CLL Practice Changing Studies From ASCO 2019: Acalabrutinib + Obinutuzumab in R/R, Superiority of Venetoclax/obinutuzumab in Elderly Patients & Comparing Frontline Options

August 2019

0 Comments
Login to view comments. Click here to Login